Buffalo Translational Consortium News
CTSA faculty and staff, leadership of Buffalo Translational Consortium (BTC) institutions and our NIH Program Officers spent a day and half immersed in our first annual CTSA Forum and Retreat. UB President Satish Tripathi and Vice President for Health Sciences and Dean, Dr. Michael Cain, made introductory comments. We reviewed our first 7 months of accomplishments and outlined one year goals and a 5-year vision for the CTSA.
The “Exploring Innovative Translational Science” keynote was provided by Co-Directors of the Clinical and Translational Science Institute, University of Rochester Medical Center, Nancy Bennett, MD, MS, Director of the Center for Community Health, Professor of Medicine & Public Health Sciences; Karl Kieburtz, MD, MPH, Senior Associate Dean for Clinical Research, Robert J. Joynt Professor in Neurology and Martin Zand, MD, PhD, Professor of Medicine, Director of Rochester Center for Health Informatics.
Results of a survey of faculty and 19 interviews with BTC leaders were presented and discussed in an effort to help us align CTSA priorities with the needs of researchers.
Through active and spirited discussions, CTSA staff and BTC leaders developed ideas and plans focused around implementing programs and mechanisms to encourage and reward team science, which is critical in advancing the field of translational science. We also took the first steps in developing a comprehensive communication plan for the CTSA, taking into account our multiple audiences, including research faculty and staff, community healthcare providers, community members, BTC leadership and our national CTSA audience.
Expect to hear more in the coming months now that our teams are in place and we are gaining momentum.
Pilot Studies in translational research were awarded to 8 groups of faculty researchers from Buffalo Translational Consortium institutions. The awards, totaling $200,000 were supported by the Clinical and Translational Science Award (CTSA).
The Translational Pilot Studies Program is designed to support the innovative, pioneering work of researchers in the Buffalo Translational Consortium (see diagram). The program is intended to develop novel methods and technologies to solve clinical and translational research problems and to foster cross-disciplinary collaborations with a goal to leverage extramural funding for larger studies.
The focus of this round of pilot studies was to:
- Facilitate clinical and translational researchers to generate preliminary data for submission of extramural research grant applications
- seek to improve clinical design, biostatistics, clinical research ethics, informatics, or regulatory pathways
- support the design, development, and validation of novel, clinically applicable devices, biomarkers, and analytical methods
A total of 78 applications were received. Review criteria included:
- Scientific merit and innovation
- Significance and impact on the field
- Potential for securing extramural funding
The following 8 proposals were awarded following a rigorous 2-tiered review process.
Multi-class Modeling of Metabonomics Data for the Detection of Early Stage Ovarian Cancer
Rachael Hageman Blair PhD, School of Public Health and Health Professions
Kunle Odunsi MD, Roswell Park Cancer Institute
Jeffrey Miecznikowski PhD, School of Public Health and Health Professions
Thomas Szyperski PhD, College of Arts and Sciences
Analysis of the Source and Significance of IgM in Sjögren’s Syndrome
Jill M. Kramer DDS PhD, School of Dental Medicine
Daniel Gaile PhD, School of Public Health and Health Professions
A Novel Electrical Stimulation Technology Changing the Paradigm for the Treatment of Orthopedic-related Infections
Mark Ehrensberger PhD, Jacobs School of Medicine and Biomedical Sciences
Anthony Campagnari PhD, Jacobs School of Medicine and Biomedical Sciences
Highly Sensitive and Portable Surface Plasmon Resonance System for Lung Cancer Early Detection
Qiaoqiang Gan PhD, School of Engineering and Applied Sciences
Yun Wu PhD, Jacobs School of Medicine and Biomedical Sciences
Daniel Gaile PhD, School of Public Health and Health Professions
Development of High-Throughput Assay for Inhibitors of Aerobactin Synthesis
Andrew M. Gulick PhD, Hauptman Woodman Research Institute
Thomas A. Russo MD, Jacobs School of Medicine and Biomedical Sciences
Inheritable Epigenetic (DNA methylation) Biomarkers and Actions of Arsenic Exposure in its Carcinogenic Activity
Xuefend Ren MD PhD, School of Public Health and Health Professions
Daniel Gaile, PhD, School of Public Health and Health Professions
Jie Wang PhD, Jacobs School of Medicine and Biomedical Sciences
Inducing Myelin Repair by Antagonism of Muscarinic Receptor Type-3
Fraser J. Sim PhD, Jacobs School of Medicine and Biomedical Sciences
Pilot Study on Pediatric Obesity Prevention by Maternal Smoking Cessation in Pregnancy and Lactation
Xiaozhong Wen MD PhD, Jacobs School of Medicine and Biomedical Sciences
Leonard H. Epstein PhD, Jacobs School of Medicine and Biomedical Sciences
Stephen T. Higgins PhD, Jacobs School of Medicine and Biomedical Sciences
Rina D. Eiden PhD, Research Institute on Addictions
Faye E. Justicia-Linde MD, Jacobs School of Medicine and Biomedical Sciences
Youfa Wang MD PhD, School of Public Health and Health Professions
Pilot Studies awardees will present the results of their work at the Clinical and Translational Research Colloquium to be held at the Clinical and Translational Research Center on a date to be announced. The Colloquium offers an excellent opportunity to discuss the new observations in a setting that is conducive to the development of new collaborations among researchers.
The Buffalo Clinical and Translational Science Award Hub Announces
The First Annual Consortium Workshop on:
Pharmacokinetics and Pharmacodynamics Modeling
Enjoy Great Science and the Beautiful Niagara Falls!
Workshops are led by world renowned leaders
in preclinical drug development and approval
This program was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award Number UL1TR001412. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
For teenagers from low-income households, trauma from bullying, parental abuse and dating violence often goes untreated since many families can’t afford traditional therapy.
In search of a less-expensive, yet effective, form of therapy, a new study led by UB behavioral health researcher Ellen Volpe will investigate the effectiveness of narrative exposure therapy (NET) in treating post-traumatic stress disorder (PTSD) and substance abuse among adolescents who have experienced multiple traumas.
The pilot study, “The Effectiveness of Narrative Exposure Therapy (NET) for Diverse Populations Experiencing Multiple Traumas,” is funded by the Mentored Career Development Award from the National Institutes of Health’s Clinical and Translational Science Awards Program.
The full article is available here.